Somaxon Pharmaceuticals, Inc.

Philip Jochelson, MD, named senior VP and chief medical officer by drug company

Published in Mental Health Business Week, May 7th, 2005

Somaxon Pharmaceuticals, Inc., a company developing products for the treatment of neuropsychiatric disorders, announced that Philip Jochelson, MD, has joined the company as senior vice president and chief medical officer.

Jochelson is responsible for leading all phases of the clinical development of Somaxon's portfolio of compounds through NDA submission and approval. He also will be responsible for medical affairs and medical marketing support for commercialized products and will also lead the medical and clinical assessment of future in-licensing opportunities.

Jochelson previously was vice president, clinical development, Neurocrine Biosciences,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Mental Health Business Week

Source: Mental Health Business Week (2005-05-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry